Development of Human Immunodeficiency Virus Type 1Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor Resistant-Strains,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Development of Human Immunodeficiency Virus Type 1Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor Resistant-Strains
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-09-13 , DOI: 10.1128/aac.01167-21
Maria E Cilento _{1,

2} , Aaron B Reeve ₃ , Eleftherios Michailidis ₄ , Tatiana V Ilina ₃ , Eva Nagy ₃ , Hiroaki Mitsuya _{5,

6,

7} , Michael A Parniak ₃ , Philip R Tedbury _{1,

2} , Stefan G Sarafianos _{1,

2}

Affiliation

4’-ethynyl-2-fluoro-2’-deoxyadenosine (EFdA, MK-8591, islatravir) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) with exceptional potency against WT and drug-resistant HIV-1, in Phase III clinical trials. EFdA resistance is not well ...

中文翻译：

从野生型或核苷类逆转录酶抑制剂抗性株开始开发人类免疫缺陷病毒 1 型

4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA, MK-8591, islatravir) 是一种核苷逆转录酶易位抑制剂 (NRTTI)，在 III 期临床试验中对 WT 和耐药性 HIV-1 具有卓越的效力. EFdA抗性不好...

更新日期：2021-09-14

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11